Multiple Analysts Downgrade NeuroPace Following Q3 Revenue Miss

On November 13, 2026, NeuroPace, Inc. faced multiple analyst downgrades following its Q3 revenue miss and the reduction of its 2026 sales guidance. Wells Fargo downgraded the stock to Equal Weight from Overweight, while JPMorgan moved its rating to Neutral from Overweight. Additionally, Leerink Partners downgraded the company to Market Perform from Outperform and set a $7 price target. These actions reflect analyst reactions to the company's updated financial outlook and recent quarterly performance.